News
NRXS
6.80
+1.95%
0.13
Weekly Report: what happened at NRXS last week (0601-0605)?
Weekly Report · 1d ago
Weekly Report: what happened at NRXS last week (0525-0529)?
Weekly Report · 06/01 10:14
Weekly Report: what happened at NRXS last week (0518-0522)?
Weekly Report · 05/25 10:17
NeurAxis Earnings Call Highlights Growth and Hurdles
TipRanks · 05/20 08:34
Weekly Report: what happened at NRXS last week (0511-0515)?
Weekly Report · 05/18 10:17
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
NASDAQ · 05/15 16:23
NeurAxis signals burn rate of $1M or less for rest of 2026 while targeting ~ $15M revenue for cash flow breakeven
Seeking Alpha · 05/12 20:42
Craig-Hallum Sticks to Its Buy Rating for NeurAxis, Inc. (NRXS)
TipRanks · 05/12 20:37
NeurAxis reports Q1 results
Seeking Alpha · 05/12 16:57
Neuraxis Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · 05/12 15:51
*Neuraxis 1Q Loss $1.76M >NRXS
Dow Jones · 05/12 11:09
Press Release: NeurAxis Reports Record First -2-
Dow Jones · 05/12 11:05
Press Release: NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
Dow Jones · 05/12 11:05
Weekly Report: what happened at NRXS last week (0504-0508)?
Weekly Report · 05/11 10:14
This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following
Barchart · 05/06 10:40
The Zacks Analyst Blog Highlights Alphabet, Walmart, Micron Technology and NeurAxis
NASDAQ · 05/05 10:34
Top Stock Reports for Alphabet, Walmart & Micron
NASDAQ · 05/04 20:11
Weekly Report: what happened at NRXS last week (0427-0501)?
Weekly Report · 05/04 10:12
Weekly Report: what happened at NRXS last week (0420-0424)?
Weekly Report · 04/27 10:15
NeurAxis Expands At-The-Market Equity Offering Capacity
TipRanks · 04/22 21:46
More
Webull provides a variety of real-time NRXS stock news. You can receive the latest news about Neuraxis Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXS
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.